Zylö Therapeutics Closes $5.225 Million Series B Financing

Zylö Therapeutics Inc., dedicated to developing a transformational drug-delivery platform, announced that it has raised $5.225 million in its Series B financing. The Series B round was led by a consortium of seasoned investors, spearheaded by James Cordes, who recently joined the Zylö board of directors. Other key participants were: (i) VentureSouth (which led the Series A round) which invested more than $1.3 million in the Series B round; (ii) the New York Angels, an angel group that has played a prominent role in both the Series A round and the Series B round; (iii) SC Launch Inc., an affiliate of the South Carolina Resource Authority (SCRA)—a non-profit corporation chartered by the state that helps fuel South Carolina’s innovation economy—which also played a significant role in both rounds; (iv) the Boston Harbor Angels, another group that showed solid support in both rounds; and (v) new investors like the Cowtown Angels, based in Ft. Worth, and the Harvard Business School Alumni Angels of Greater New York. Read more >>